individual peptides revealed four that could be isolated from two or more allotypes. Members of the closely related HLA-B22 family -HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601 -show only minor differences in their peptide-binding specificities. This marked similarity is reflected at the functional level, as alloreactive cytotoxic T lymphocytes generated against HLA-B*5401 and HLA-B*5501 exhibited crossreactive recognition.
Conclusion:
The isolation of identical endogenously bound peptides from six HLA-B allotypes demonstrates overlap in the repertoires of peptides bound in vivo by different allotypes. We speculate that the shared preference for binding peptides with proline at position 2 reflects a selective pressure to retain this specificity, which may be based upon peptide availability in vivo. Characterization of the overlap between the repertoires of peptides bound by HLA-B allotypes could simplify the development of peptide-based vaccines that are targeted to cytotoxic T cells, as single peptides would be effective for humans of different HLA types.
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Background
Class I molecules of the major histocompatibility complex (MHC) are polymorphic glycoproteins that bind peptides and present them to cytotoxic T lymphocytes; they also regulate cell lysis by natural killer lymphocytes. Both cytotoxic T cells and natural killer cells provide defence against cells infected with intracellular parasites, including viruses, or cells that have undergone malignant transformation. Class I proteins comprise a polymorphic class I heavy chain non-covalently associated with 32-microglobulin. The oti and or2 domains of the class I heavy chain form a binding site which is occupied by a single peptide, usually nine amino acids long. Although peptides of diverse amino-acid sequence can be bound by a single class I allotype, each allotype binds a defined repertoire of peptides that share a sequence motif (reviewed in [1] ), with motifs comprising one-or two conserved positions known as anchors. Variation at the other positions allows binding of many thousands of different peptides by a single allotype [2] .
Motifs can be deduced by sequence analysis of peptide pools [3] or by alignment of individual peptides bound by a given allotype [4, 5] . Studies to date show that, for peptides bound by products of the HLA-A and HLA-B human class I MHC loci, anchor residues at position 2 and the carboxyl terminus predominate. Amino-acid preferences at anchor positions are characteristic of each class I allotype, and the crystal structures of HLA molecules show that specificity results from complementary interactions with polymorphic subsites, or pockets, in the peptide-binding site [6] [7] [8] . As differences between alleles focus on residues that line the peptide-binding site, the current view is that polymorphism serves to change the repertoire of peptides bound. Class I polymorphism is relatively even within human populations, such that there are no dominant allotypes. So far, 50 HLA-A, 97 HLA-B and 34 HLA-C alleles, obtained from a range of ethnic groups, have been identified [9] . But the extent to which each allele's product binds a unique repertoire of peptides has yet to be assessed.
Experiments using various assay systems in vitro have suggested that binding of peptide to class I molecules is predominantly allotype-specific [10] [11] [12] . The paucity of peptides binding to more than one allotype reflects drastic differences in the peptide anchor residues preferred by Correspondence to: Linda Barber. different allotypes. For example, HLA-A*0201 selects peptides with leucine at position 2 [3] , whereas HLA-B*2705 prefers those with arginine at this position [4] . Even the closely related HLA-A*0201 and HLA-A*0205 allotypes, which differ only at four amino-acid residues, exhibit substantial differences in their bound-peptide motifs [13] . There are, however, reports of synthetic peptides binding to more than one allotype. Examples of HLA-A*0201-binding peptides binding also to other HLA-A allotypes have been described [14] . Certain peptides bound by HLA-A3 can also bind to HLA-A11 [15] , whereas others bind to HLA-A1 [16] , and screening for potential T-cell epitopes in malaria parasite proteins revealed many peptides that bind both HLA-B*5301 and HLA-B*5101 [17] . Of particular note, peptides able to bind both HLA-B*2705 and HLA-A3, two molecules with divergent sequences that are products of different loci, have been described [12, 18] .
New class I alleles arise primarily as a result of re-assortment of gene segments from existing alleles, rather than by acquisition of unique substitutions [19] . As sequence variation is concentrated within the peptide-binding site, products of recombinant class I alleles might be expected to have recombined peptide-binding specificities. To investigate this hypothesis, we examined the peptide-binding preferences of six serologically cross-reactive HLA-B allotypes that differ in pair-wise comparison by 1-17 positions in their al and or2 domains (Fig. 1) . HLA-B*5401 and HLA-B*5502 (found mainly in oriental populations), and HLA-B*5501 and HLA-B*5601 (found at highest frequency in Caucasians), are members of a closely related family called HLA-B22. These four subtypes probably evolved one from another by a series of simple gene recombinations [20] , each of which introduces one or two residue changes ( Fig. 1 and highlighted residues in Fig. 2 ) within the peptide-binding site. Forty of the HLA-B alleles defined so far were probably formed by recombinations analogous to those seen in the HLA-B22 family [21] .
In this study, the endogenous peptides bound by HLA-B*5401, HLA-B*5501, HLA-B*5502, HLA-B*5601, HLA-B*6701 and HLA-B*0702 have been characterized. Comparison of the peptide-binding specificities of HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601 allowed us to assess the functional impact of small changes typical of those acquired during the evolution of new alleles. Inclusion of HLA-B*0702 and HLA-B*6701 in the panel of allotypes studied allowed the effects of more drastic sequence differences on peptide-binding specificity to be assessed. The common feature of these six allotypes is an identical a-helix in the al domain (residues 57-84). For HLA-B*0702 and HLA-B*6701, sequence identity extends throughout the al domain [22] . These two allotypes differ, however, at eleven positions in their a2 domains [22] , six of which contribute to formation of the peptide-binding site (Fig. 2) . HLA-B*0702 is a common allotype present in African, European and Asian populations. In contrast, HLA-B*6701 is rare and confined mainly to oriental populations. Our results have potential clinical implications, as well as shedding light on the evolution of HLA class I alleles.
Results
Characterization of peptide-binding motifs reveals a shared preference for proline at position 2 In our experiments, we exploited the specificity of the ME1 monoclonal antibody [23] for HLA-B molecules that have either alanine-glutamine-alanine or alaninelysine-alanine at positions 69-71 of their aol helix. Expression of the ME1 epitope by members of the HLA-B22 family and by HLA-B*0702 and HLA-B*6701 (indicated in Fig. 2 ) [22, 23] enabled us to purify these molecules from cell lines derived from heterozygous individuals.
Peptide specificities were determined by sequencing pools of endogenously bound peptides eluted from purified class I molecules. Peptide pools were subjected to 14 cycles of Edman-degradation sequencing. Experiments were repeated at least twice, and, to prevent possible contamination between peptides derived from different allotypes, separate batches of ME1 antibody were used to purify each allotype. Representative results are shown in Table 1 . No significant phenylthiohydantoin (PTH) amino-acid signals were detected in cycles 10-14, so most peptides are nine amino acids or fewer in length. Results of the pool sequence analysis are summarized in Table 2 .
The most striking feature of the peptide motifs defined by this analysis is that, for all six allotypes, the dominant anchor residue is proline at position 2 (numbered in relation to the amino terminus). No other positions were so completely dominated by a single amino acid. Position 9, the carboxyl terminus of the peptide, was the only other position for which increases in just one or two amino acids were observed, and here allotypic differences were evident. The more divergent allotypes, HLA-B*0702 and HLA-B*6701, prefer leucine, whereas members of the HLA-B22 family -HLA-B*5401, HLA-B*5501, (Table 1) . Thus the dominant anchor residues in the peptides bound by the six allotypes examined in this study are found at position 2 and the carboxyl terminus.
For peptide positions other than 2 and 9, increases in many amino acids were observed. Some conservation at positions I and 3 was noted, however, suggesting these sites may represent secondary anchors. Increases in arginine, methionine, tyrosine and phenylalanine were seen consistently at position 3 of the peptides bound by HLA-B*0702, HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601. A distinguishing characteristic of the HLA-B*6701 peptide pool was absence of the positively charged amino acids, arginine and lysine, at position 3. Residue preferences at position 1 were difficult to assess because comparison with previous cycles was not possible and free amino acids present in some samples raised the non-specific background. But comparison of the yields for each amino acid in cycle 1 suggested that some selection may occur at position 1. For all allotypes except HLA-B*5401, alanine consistently formed more than 20 % of the total yield at cycle 1. For HLA-B*5401, weak preferences for methionine and phenylalanine were indicated: these residues generated 17 % and 7 %, respectively, of the total signal at position 1 (values of 11 % and 12 %, respectively, were obtained in a repeat experiment; data not shown). For the other allotypes, methionine and phenylalanine never constituted more than 5 % and 3 %, respectively, of the yields obtained in cycle 1.
Characterization of individual peptides reveals overlapping repertoires of endogenously bound peptides
Sequence analysis of pools of peptides bound by class I molecules reveals the dominant peptide-binding motif. To gain further knowledge of the types of peptide bound, individual sequences present in well-resolved peaks from reverse-phase high performance liquid chromatography (HPLC) separations were analysed by Edman degradation. Sequences were confirmed by analysis of peptide molecular weights. The results obtained from peptides associated with HLA-B*0702, HLA-B*5501, HLA-B*5502 and HLA-B*5601 are shown in Table 3 .
Individual sequences confirmed the peptide-binding motifs defined by pool sequence analysis. Most peptides were nonamers, with the exception of one peptide bound by HLA-B*0702 which was a decamer. In most cases, dominant anchors identified by pool sequence analysis at positions 2 and 9 were present. Some additional residue preferences were also revealed, however. Although pool sequencing identified a preference for leucine at the carboxyl terminus of HLA-B*0702-bound peptides, sequences of individual peptides showed that alanine and valine are also tolerated. This indicates that a subset of HLA-B*0702-binding peptides have the same motif as that defined by pool sequencing of the peptides bound by members of the HLA-B22 family -namely, proline at position 2 and alanine at position 9. More importantly, it suggests that certain peptides bound by HLA-B*0702 will also bind HLA-B22 allotypes.
The hypothesis of overlap between the repertoires of bound peptides was proven correct by the isolation of identical endogenously bound peptides from different HLA-B allotypes (Table 3 ). Four such peptides were identified, and for three of them, analysis of the data-base of protein sequences revealed a cellular protein from which the peptide was likely to have been derived. One peptide, which is identical to part of the HLA-DP signal sequence, was found to be bound by HLA-B*0702, HLA-B*5501, HLA-B*5502 and HLA-B*5601. The second peptide, identical to residues 37-45 of -actin [24] , was isolated from HLA-B*0702 and HLA-B*5502. Both HLA-B*5502 and HLA-B*5601 bind the third peptide, which has a sequence identical to residues 6-14 of the LMP2 protein [25] . The fourth peptide, having the sequence Ala-Pro-Arg-Gln-Pro-Gly-Leu-Met-Ala, was present in the peptides extracted from HLA-B*5501, HLA-B*5502 and B*5601, and was isolated from HLA-B*0702 by Engelhard et al. [26] . Of the nine different peptide sequences defined in this study, four were isolated from more than one allotype, suggesting considerable overlap in the endogenous peptides bound by these HLA-B allotypes.
For five of the individual peptides sequenced, a human protein was identified from which they were likely to have been derived. These were all intracellular proteins, consistent with accumulated observations that class I molecules bind peptides derived from intracellular proteins (reviewed in [1] ). The major pathway for generating peptides that are then bound by class I molecules involves partial protein degradation in the cytoplasm, followed by transport of peptides into the endoplasmic reticulum, where they bind newly synthesized class I molecules. Of particular interest, a peptide bound by both HLA-B*5502 and HLA-B*5601 has an exact match to LMP2. LMP2 is an MHC-encoded component of the proteolytic complex known as the proteasome, which is implicated in the generation of class I-bound peptides. Mouse LMP2 is synthesized as a precursor, from which the amino-terminal sequence is cleaved prior to incorporation of LMP2 into proteasomes [27, 28] . The class Ibound peptide from human LMP2 derives from a sequence homologous to part of this cleaved region, suggesting that human LMP2 undergoes similar post-translational processing. Peptides that are generated by cleavage of signal sequences from proteins following their translocation into the endoplasmic reticulum represent a second source of class I-binding peptides [29] . Isolation of the HLA-DP signal sequence peptide from four allotypes emphasizes the contribution of this pathway to the bound-peptide repertoire.
Members of the HLA-B22 family are functionally similar HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601 have very similar peptide-binding specificities. Analysis of the peptide pools eluted from these HLA-B22 subtypes showed that differences were confined to minor variation in amino-acid signals at non-anchor positions 4-8, along with differential amino-acid selection at the secondary anchor position, at the amino terminus of peptides bound by HLA-B*5401. Similarity in peptide binding by these four allotypes correlates with relatedness of their heavy chains, which differ at only 1-3 amino acids (Fig. 1) . The closely related subtypes HLA-B*4402 and HLA-B*4403, which differ only by a single aminoacid substitution in the peptide-binding site, also have markedly similar peptide-binding motifs [30] . Despite apparent equivalence, a strong alloreactive cytotoxic T-cell response is generated between these two allotypes, both in vitro [31] and in vivo upon bone marrow transplantation [32] . The ability of cytotoxic T cells to distinguish between HLA-B*4402 and HLA-B*4403 is thought to reflect formation of distinct conformational epitopes by the same peptides presented in the context of different class I molecules [30] .
To test whether the functional impact of polymorphism within the HLA-B22 family is also manifest at the level of cytotoxic T-cell recognition, we compared the capacity of alloreactive cytotoxic T cells raised against either HLA-B*5401 or HLA-B*5501 (which differ at three amino acids) to cross-react with the other allotype. (Fig. 3a) . Similarly, for the cytotoxic T cells stimulated with HLA-B*5501, 73.7 % (14/19) were cross-reactive with HLA-B*5401 and 85.7 % of these recognized both allotypes equally (Fig. 3b) . In contrast, there was no cross-recognition of alloreactive cytotoxic T cells raised against HLA-B*5401 or HLA-B*5501 with the more divergent allotype HLA-B*2705 (data not shown). Similar results were obtained with peripheral blood lymphocytes from a second donor of different class I haplotype (data not shown). This result demonstrates the functional similarity of HLA-B*5401 and HLA-B*5501, as many alloreactive cytotoxic T cells fail to distinguish between these two HLA-B22 subtypes.
Discussion
Many class I allotypes prefer peptides with proline at position 2 In human populations, HLA-B is the most polymorphic of the MHC class I gene loci, and HLA-B alleles provide the clearest associations of class I with disease outcome [33, 34] . Of the 97 HLA-B alleles defined to date, almost every pair of alleles can be distinguished by at least one residue of the peptide-binding site, suggesting that new HLA-B alleles are selected for novelty in their peptidebinding specificity. We define here the peptide-binding specificity of six HLA-B allotypes that differ by 1-9 residues of their peptide-binding sites but have an identical sequence in their ctl helices. Despite their sequence differences, all six allotypes exhibit a strong preference for binding peptides with proline at position 2. Indeed, their peptide-binding motifs are sufficiently similar that HLA-B*0702 and members of the HLA-B22 family can bind identical peptides. This finding is the first demonstration that identical endogenously bound peptides can be isolated from a number of different allotypes. Previous observations of individual peptides binding more than one allotype have been confined in vitro to assays using synthetic peptides [12, [14] [15] [16] [17] [18] . Our study shows that overlap in the repertoires of peptides bound by class I allotypes occurs in vivo. Of note, isolation from four allotypes of a peptide identical to part of the HLA-DP signal sequence highlights the significant role that post-translational processing of proteins has in the supply of endogenous peptides for binding to class I molecules.
Combining our results with those of previous analyses reveals that proline at position 2 is a common feature of the peptide-binding motif of class I molecules. In addition to the six allotypes examined in this study, a proline anchor at position 2 has been reported for HLA-B*5301 [17] , HLA-B*3501 [17, 35] , HLA-B*5101 [17, 36] and mouse H-2Ld [37] . Moreover HLA-B*0801 exhibits a preference for proline at position 2, although it does not constitute the dominant specificity [16] , and several HLA-C allotypes also accommodate peptides with this motif [38] .
The shared preference for peptides containing proline at position 2 among allotypes with divergent sequences demonstrates that not all polymorphisms confer drastic change on the repertoire of bound peptides. Evidently, certain key features of the peptide-binding sites are shared. To facilitate structural analysis and correlations with the function of class I molecules, the peptide-binding site can be delineated into six specificity pockets, A-F, (Fig. 4) [7] . The B pocket accommodates the dominant anchor residue at position 2 of peptides bound in the crystal structures of HLA-A*0201 and HLA-B*2705 [7, 39] , and common to all allotypes that bind peptides with proline at position 2 is a large bulky aromatic residue within the B pocket (Table 4 ). In the six allotypes we examined, the aromatic residue of the B pocket is provided by tyrosine at position 67. Although no crystal structures are available for allotypes with specificity for proline-containing peptides, Madden et al. [8] speculated that the presence of an aromatic residue at position 67 would substantially fill the position-2-binding pocket, creating a small hydrophobic subsite. Molecular modelling of HLA-B*0702 shows that the proline side chain can fit in such a B pocket [40] .
The aromatic residue that appears to confer selectivity for proline varies between tyrosine and phenylalanine according to the allotype, as does its location (position 45 or 67), but the functional effect is the same. So far, all allotypes with an aromatic amino acid at position 45 
The advantage of binding proline-containing peptides
That class I allotypes of divergent sequence have the same preference for binding peptides with proline at position 2 is good evidence for independent or convergent evolution of this specificity. In turn, this observation suggests that there has been a selective advantage for class I molecules to bind proline-containing peptides. We speculate that this advantage is related to the intracellular supply of peptides. Peptide-binding facilitates cell-surface expression of class I molecules by promoting assembly of stable, properly folded complexes [41] [42] [43] [44] . Evidence suggests that peptide supply is a limiting factor in the assembly of class I molecules [45] . Under such circumstances, it might be expected that class I peptide-binding sites would evolve to exploit the most abundant populations of available peptides.
The peptides bound by class I molecules are derived mainly from intracellular proteins that have undergone partial proteolysis in the cytoplasm. An endopeptidase complex, the proteasome, is believed to contribute to peptide generation [46] and has activities similar to trypsin, chymotrypsin and peptidylglutamyl-peptide hydrolase (reviewed in [47, 48] ). Because of proline's unique cyclic imino structure, peptide bonds involving proline are relatively resistant to cleavage by many exopeptidases and endopeptidases, including amino-and carboxy-peptidases, trypsin, chymotrypsin, and signal peptidases [49, 50] . As a consequence, the cellular pool of potential class I-binding peptides may be enriched in proline-containing peptides. Adaptation to the available supply of endogenous peptides could increase the effectiveness of class I molecules in their selection and stimulation of lymphocyte receptors.
Evolution of peptide-binding specificity in the HLA-B22 family
Formation of new HLA-B alleles most frequently involves gene recombination events that replace a short segment of one allele with the homologous region of another [19] . Typically these exchanges produce two or three amino-acid substitutions in the peptide-binding site. Many families comprising up to 16 alleles that differ in this way have been described [21] .
In this study, the peptide-binding specificities of four subtypes from the HLA-B22 family were analyzed. The subtypes appear to be evolutionarily related by simple recombinations and differ by 1-3 substitutions in their peptide-binding sites [20] . Despite these differences, the repertoires of peptides bound by the HLA-B22 subtypes are remarkably similar. The peptide-binding motifs are very similar, and identical peptides are present in the peptide pools isolated from different HLA-B22 subtypes. Of note, the main difference observed was differential selection of amino acids at position 1 (a secondary anchor) of peptides bound by HLA-B*5401. This subtype appears to have been generated by a rare inter-locus gene recombination involving HLA-B*5502 and an HLA-C allele [20] . The result is that HLA-B*5401 has a combination of residues otherwise unique to HLA-C allotypes, namely glycine at position 45 and valine at 52. Despite this difference, however, comparison of alloreactive T cells raised against HLA-B*5401 and HLA-B*5501 showed that many cannot differentiate between these two subtypes.
Evident from these results is that the recombination events that generated the HLA-B22 subtypes did not produce major alterations in the types of peptides bound or their presentation to cytotoxic T cells. If differences exist, they are subtle, and their identification will require more extensive analysis of individual peptides and cytotoxic T-cell clones. If the subtypic similarities seen in the HLA-B22 family are reiterated in other class I HLA families, there are significant medical implications. In clinical transplantation, for example, the capacity of subtypic differences to stimulate either graft rejection or graft-versus-host disease has been questioned [51] . Certain subtypic differences are known to stimulate alloreactions [31, [52] [53] [54] , but that may not be true for all such differences and identification of those differences that do not will increase the probability of matching unrelated donors and recipients for transplantation.
Conclusions
Despite multiple differences at residues comprising the peptide-binding site, a group of class I HLA-B allotypes were found to have such similar peptide-binding specificities that they can bind identical peptides. Oir study is the first to describe isolation of identical endogenously bound peptides from several class I allotypes, thereby demonstrating in vivo the relevance of overlapping peptide repertoires. The finding that groups of allotypes bind the same peptides has the potential to reduce the complexity of peptide-based vaccines aimed at stimulating cytotoxic T-cell responses against intracellular pathogens. This observation also suggests that future attempts to correlate disease with class I HLA type on the basis of peptide-binding specificities may reveal associations not seen in correlations made using individual allotypes. proteins. An IgG2a switch variant of the mouse monoclonal antibody MEI [55] was used to purify the allotypes indicated in bold. The MEI antibody exhibits specificity for HLA-B*7, B*27, B*42, B*54, B*55, B*56 [23, 55] , HLA-B*6701 [22] and HLA-B*7301 [56] .
Materials and methods
Cell lines and antibodies
Class I purification and isolation, and separation of bound peptides
Cells were lysed in 20 mM Tris-HCI pH 8, 150 mM NaCl buffer containing 1.5 % nonidet P-40 (NP-40), 2 mM phenylmethylsulphonyl fluoride, 100 Rm iodoacetamide, 5 g ml-' aprotinin, 5 g ml-' leupeptin, 5 zg ml-1 pepstatin A, 1 mM EDTA and 0.2 % sodium azide. Class I proteins were purified from cell lysates by immunoaffinity chromatography using the monoclonal antibody ME1. Antibody was purified using affigel protein A agarose (BioRad, Richmond, California), and then covalently coupled to protein A Sepharose (Pharmacia LKB, Uppsaala, Sweden) using dimethyl pimelimidate-2 HCI. Antibody was coupled at 5 mg ml-1 beads (wet volume) and 10 mg antibody in total was used for purification from lysates made from 101°cells.
The lysate was passed initially through a column containing 2ml protein A Sepharose at a flow rate of 0.5 ml min -1 to remove components that adhere non-specifically to the matrix. This was followed by overnight incubation of the lysate with the affinity matrix using slow rotation. These, and all subsequent steps in the purification procedure, were performed at 4 C. The affinity matrix was placed in a column and the lysate applied at a flow rate of 0.5 ml min -1 . After sample application, the column was washed consecutively with 20 column volumes each of the following three buffers: 20 mM Tris-HCI pH 8, 150 mM NaCI, 1 % NP-40; 100 mM Tris-HCI pH 8, 0.5 M NaCI; and 100 mM Tris-HCI pH 8. Class I protein was then eluted with 10 ml 0.2 N acetic acid (pH 2.7) and collected as I mil fractions. Protein purity and concentration were assessed by SDS-polyacrylamide gel electrophoresis.
Fractions containing class I protein were made to 10 % acetic acid and incubated at 75 C for 15 min to denature class I complexes and release bound peptides. The mixture was cooled to room temperature and the peptides separated from denatured protein by ultrafiltration using a Centricon 3 filtration unit (3 000 Dalton cut-off membrane; Amicon, Beverly, Massachusetts). The peptide-containing filtrate was concentrated by vacuum centrifugation to a volume of 100 pil. Peptides were separated on a C18 reverse-phase column (2.1 mmn internal diameter x 15(0 mm length; Vydac) using an HPLC (model 140B solvent delivery system; Applied Biosystems, Foster City, California). Peptide mixtures were loaded in 10 % acetic acid and the column eluted using gradients made from 0.06 % trifluoroacetic acid in water (buffer A) and 0.05 % trifluoroacetic acid in 80 % acetonitrile with water (buffer B) at a flow rate of 150 I min 1 . A gradient starting from 5 % buffer B, rising to 55 % B at 100 minutes and then increasing to 95 % B at 120 minutes, was used. The column eluate was monitored spectrophotometrically for absorbance at 214 nm (Applied Biosystems 785A absorbance detector) and individual peaks of absorbance were collected manually in 1.5 mnl microfuge tubes. Each fraction was quickly frozen on dry ice and stored at -70 C.
Automated Edman degradation sequencing
Peptide-binding motifs of class I molecules were deduced by sequencing mixtures of eluted peptides -'pool sequencing'. This approach is based on the assumption that a dominant,'signal for an amino acid at a particular cycle in the sequencing reaction indicates the presence of that amino acid at that position in a majority of the peptides. HPLC fractions collected at 7-40 % buffer B in the gradient were pooled, concentrated by vacuum centrifugation, and subjected to amino-acid sequence analysis on an Applied Biosystems model 476A automated protein sequencer operated in gas-phase mode. The results were analyzed using model 610A data analysis software from Applied Biosystems. As cysteine was not modified, it was not detectable; in some cases, tryptophan was not assigned as it co-elutes with a byproduct of the sequencing reaction.
Interpretation of the results of the peptide pool sequencing was performed using raw data. Values below pmole were ignored. Amino acids obtained at each cycle of the sequencing reaction were grouped into the following categories, with assignments listed in order of decreasing yields of the PTH amino acids: dominant, yield of a single amino acid increases several fold over that in the previous cycle; strong, amino acids having a more than 2-fold increase over that obtained in the previous cycle; weak, residues with an increase of 1.5-2-fold over the previous cycle. Because comparison with previous cycles was impossible for cycle 1, analysis of this position was performed by calculation of percent molar yields for each amino acid.
To characterize individual peptides, well-resolved peaks from separation of the peptide pools were subjected to analysis by Edman degradation sequencing. To confirm the sequences obtained, small aliquots (10 %) of the fractions were analyzed by mass spectrometry to obtain molecular weight measurements. In some cases, further verification was obtained from partial sequences obtained by tandem mass spectrometry. A search of the GenBank data-base using the Wisconsin Genetics Computer Group programs [57] and a VAX 4000-90 computer was performed to identify proteins from which peptides sequenced could be derived.
Mass spectrometry Molecular weights of individual peptides were measured by electrospray ionization mass spectrometry on a SCIEX API III triple quadrupole mass spectrometer (SCIEX, Thornhill, Canada). Peptides were monitored by capillary HPLC-mass spectrometry using the same buffers and gradient as described above, at a flow rate of 2 I min -1 . The column (180 .m internal diameter x 15 cm length) was packed with 5 Rm particle size C18 matrix (LC Packings, San Francisco, California). The quadrupole mass spectrometer was operated with the ionspray articulated nebulizer at 4600 V, the interface plate at 600 V, and the orifice at a range of 80-120 V. Data were collected every 0.1-0.25 u with the quadrupole scanning from 600-2200 u in 32 seconds. Mass resolution was set to 1000 m/Am, allowing assignment of singly charged and doubly charged peptide ions. Collision-induced dissociation experiments used argon as the collision gas at 50-60 eV to fragment peptides.
Assessment of cytotoxic T-cell cross-reactivity by split-well analysis at limiting dilution
Limiting dilution experiments were conducted as described previously [58] . Human peripheral blood lymphocytes were obtained by Ficoll separation of heparinized blood from healthy donors and cryopreserved until required. Donor class I alleles were characterized by DNA sequence analysis according to the protocol described by Domena et a. [59] as: donor 1: --HLA-A*0101, -A*0301; -B*0702, B*1501; -Cw0302--; donor 2: --HLA-A*0201, -A*0301, -B*40012, -B*5001, -Cw0602--. Donor peripheral blood lymphocytes were thawed and plated at 0.6 x 103, 1.2 x 103, 2.5 x 103 and 5 x 103 cells per well (24 replicates per concentration) into round-bottom microtitre wells in RPMI 1640 medium supplemented with 10 % fetal bovine serum (HyClone, Logan, Utah), 2 mM L-glutamine, 5 x 10 -5 M ,B-mercaptoethanol, 100 U ml -I penicillin, 100 Rg ml-streptomycin and 5 U recombinant interleukin-2 per ml. Constant numbers (5 x 104) of irradiated (2000 rad) stimulator cells were added to each well and the plates incubated at 37 C in a humidified atmosphere containing 5 % CO 2 . After 5 days, each well was split and equal aliquots incubated with a panel of 5 lCr labelled target cells ( x 103) for 4 hours at 37 C. Supernatants were harvested and assayed for 51 Cr radioactivity using a gamma counter. Wells in which cytotoxic T-cell lysis of target cells resulted in specific release of > 10 % of the radioactivity were considered positive. Cytotoxic T-cell cross-reactivity was assessed by correlating responses of individual positive wells at limiting dilutions to the panel of target cells.
Cells used as stimulators were EBV-transformed B lymphoblastoid cell lines LKT-3 (HLA-A24, B5401, Cw3) and VEN (HLA-A3,A31, B18, B*5501, Cw3,CwS). The HLA-A, -B and -C negative EBV-transformed B lymphoblastoid cell line 721.221 [60] transfected with HLA-B*5401, HLA-B*5501 or HLA-B*2705, as described by Litwin et al. [61] , were used as targets. On the day of assay, stable and comparable expression of the transfected class I alleles was confirmed by immunofluorescent staining and flow cytometric analysis.
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